Skip to main content
Health Gate Turkey

Heart Failure & Transplant

Heart Failure & Transplant in Turkey

Heart failure and transplant care in Turkey follows a staged pathway rather than moving directly from diagnosis to transplantation. Treatment can include guideline-directed medicines, cardiac devices, specialist procedures, mechanical circulatory support, and heart transplantation for carefully selected patients. A donor heart comes from deceased donation and enters Turkey's regulated national allocation system.

When Does Heart Failure Become Advanced Enough for Transplant Assessment?

Transplant assessment becomes relevant when severe heart failure persists despite appropriate treatment and other clinically suitable options. Advanced disease is not defined by ejection fraction alone. Repeated hospital admissions, worsening symptoms, poor exercise capacity, low blood pressure, or progressive organ dysfunction can trigger specialist referral. Dependence on intravenous medicines or temporary circulatory support can also indicate advanced disease. The 2024 ISHLT transplant-candidate guideline requires assessment across several clinical domains rather than one numerical threshold. Referral for evaluation does not mean transplantation will follow. An advanced heart-failure team first reviews reversible causes and remaining treatment options.

Which Treatments Can Be Considered Before Heart Transplantation?

Advanced heart-failure care can include several treatments before transplantation becomes the selected pathway.

  • Medical therapy: Guideline-directed medicines remain important when tolerated and clinically appropriate.

  • Cardiac devices: Selected patients can require CRT, ICD therapy, or other rhythm-related treatment.

  • Corrective procedures: Coronary, valve, rhythm, or congenital interventions may address contributing cardiac problems.

  • Mechanical support: An LVAD can support circulation in selected patients with advanced ventricular failure.

  • Heart transplantation: Suitable candidates can enter transplant evaluation when other strategies cannot adequately address advanced disease.

The appropriate sequence depends on heart-failure cause, organ function, anatomy, previous treatment, and overall clinical condition.

How Is an LVAD Different From a Heart Transplant?

An LVAD supports the failing ventricle mechanically, while transplantation replaces the diseased heart with a donor heart. A durable left ventricular assist device moves blood from the left ventricle into systemic circulation. It can serve as a bridge while an eligible patient awaits transplantation. Selected patients who cannot receive transplantation may use durable support as long-term therapy. An LVAD also introduces device-specific issues, including infection, bleeding, thrombosis, stroke, and ongoing equipment management. Turkish public heart centers document mechanical circulatory support alongside heart-transplant programs. Receiving an LVAD does not automatically guarantee later placement on a transplant waiting list.

How Are Donor Hearts Allocated in Turkey?

Deceased-donor hearts in Turkey are allocated through the Ministry of Health's national coordination and software system. Current transplant regulations require deceased-donor organs to pass through this centralized allocation framework. Patients must be registered within the Ministry software before receiving a deceased-donor organ. The regulations also prohibit individualized arrangements that bypass the established distribution process. Heart donation differs from living-donor kidney or liver transplantation because a living person cannot donate a heart. Consequently, health-tourism authorization does not create a separate route to a donor organ. International patients must confirm listing eligibility directly with an authorized heart-transplant center.

What Is Checked Before a Patient Can Be Listed for Heart Transplantation?

Heart-transplant listing requires a multidisciplinary evaluation of cardiac severity, other organs, infection risks, and long-term treatment feasibility. The 2024 ISHLT guideline updates candidate assessment across medical and psychosocial domains. Evaluation can include heart function, pulmonary circulation, kidney and liver status, infections, malignancy history, vascular disease, and nutritional condition. Teams also review treatment adherence and the ability to manage complex post-transplant care. Some findings may be reversible before final listing decisions. Others can make transplantation inappropriate or require another advanced-heart-failure strategy. Transplant candidacy is therefore a continuing clinical assessment rather than approval based only on severe symptoms.

What Happens After Heart Transplantation?

Heart-transplant recipients require lifelong specialist monitoring because transplantation replaces the heart but does not end medical treatment. Immunosuppressive medicines reduce the immune response against the donor organ. Uninterrupted access to these medicines is important because inadequate immunosuppression can increase rejection risk. Follow-up can include clinical review, laboratory monitoring, cardiac imaging, and transplant-specific testing. Doctors also monitor infections, kidney function, medication toxicity, vascular disease, malignancy risk, and other long-term complications. ISHLT guidance treats rejection management and long-term prevention as separate components of post-transplant care. International patients need a documented follow-up pathway before returning home.

What Should International Patients Verify Before Heart Failure or Transplant Care in Turkey?

International patients should verify both health-tourism authorization and specific heart-transplant capability before arranging advanced heart-failure care in Turkey.

  • Provide echocardiography, angiography, cardiac MRI, catheterization, and recent laboratory records when available.

  • Include previous CABG, valve surgery, PCI, ablation, pacemaker, ICD, CRT, or LVAD documentation.

  • Confirm whether the hospital holds the required organ-specific heart-transplant activity authorization.

  • Ask how national waiting-list and deceased-donor allocation rules apply to the individual case.

  • Establish medication, rejection monitoring, emergency care, and transplant follow-up arrangements before returning home.

The Ministry's international health-tourism provider page was updated on July 28, 2026. Authorization does not guarantee transplant eligibility.

Heart Failure & Transplant in Turkey Cost 2026: What Affects the Total Cost?

Heart failure and transplant care in Turkey has no single 2026 cost because each patient's clinical pathway differs substantially. This page therefore provides no fixed treatment price. Costs can depend on advanced cardiac testing, hospitalization, intensive care, medicines, implanted devices, or mechanical circulatory support. Transplant evaluation and post-transplant monitoring create additional requirements when transplantation becomes relevant. LVAD care follows a different financial pathway from donor-heart transplantation. Complications and prolonged treatment can also change total requirements. International patients should request an individualized written quotation after clinical assessment, with medicines, devices, hospitalization, follow-up, and exclusions clearly identified.

This content provides general medical information and does not recommend heart transplantation, LVAD treatment, a healthcare provider, or a clinical outcome. Advanced heart failure requires individualized specialist assessment.

Last updated: August 14, 2026

Sources

  • https://www.ishlt.org/education-and-publications/standards-guidelines-detail/ishlt-guidelines-for-the-evaluation-and-care-of-cardiac-transplant-candidates

  • https://www.ishlt.org/education-and-publications/standards-guidelines-detail/ishlt-guidelines-for-the-care-of-heart-transplant-recipients

  • https://www.ishlt.org/education-and-publications/standards-guidelines-detail/recommendations-for-use-of-maintenance-immunosuppression-in-solid-organ-transplantation

  • https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/acute-and-chronic-heart-failure/

  • https://www.escardio.org/guidelines/scientific-documents/scientific-statements/heart-failure/

  • https://www.escardio.org/communities/councils/cardiology-practice/education/cardiopractice/durable-therapies-in-advanced-chronic-heart-failure/

  • https://antalyaism.saglik.gov.tr/TR-266691/organ-nakli-hizmetleri-yonetmeligi.html

  • https://sggm.saglik.gov.tr/TR-111303/organ-bagisi-kampanyasi-2025.html

  • https://izmirataturkeah.saglik.gov.tr/TR-204182/kardiyoloji-klinigi.html

  • https://mehmetakifersoyeah.saglik.gov.tr/TR-796434/uluslararasi-hasta-birimi.html

  • https://shgmturizmdb.saglik.gov.tr/EN-69061/authorized-healthcare-providers-and-facilitators.html

  • https://shgmturizmdb.saglik.gov.tr/EN-108974/regulation-on-international-health-tourism-and-tourist-health.html

  • https://shgmturizmdb.saglik.gov.tr/TR-117812/saglik-turizmi-yetki-belgesine-sahip-saglik-tesislerinin-dikkatine.html

  • https://antalyaism.saglik.gov.tr/TR-366500/saglik-hizmetlerinde-tanitim-ve-bilgilendirme--faaliyetleri-hakkinda-yonetmelik.html